Quality of life in subjects with Castration Resistant Prostate Cancer (mCRPC) treated with taxane: An IRONMAN registry analysis
Divyan Chopra
Poster presented at ISPOR 2026
[177Lu]Lu-PSMA-617 (177Lu-PSMA-617) in combination with an androgen receptor pathway inhibitor (ARPI) vs. 177Lu-PSMA-617 alone for the treatment of metastatic castration-resistant prostate cancer (mCRPC): a real-world prostate cancer disease observation (PRECISION) data platform analysis
Elisabeth Heath
Poster presented at ASCO GU 2026
Classification tree risk phenotypes for early treatment limiting toxicity after androgen receptor pathway inhibitor initiation in metastatic hormone naive prostate cancer
Alexandra Larkin and Nabiel Mir
Poster presented at ASCO 2026
Clinical outcomes among patients with metastatic hormone-sensitive prostate cancer in contemporary real-world US clinical practice: a PRostatE Cancer diSease observatION (PRECISION) data platform analysis
Alton Oliver Sartor et al.
Poster presented at ASCO GU 2026
Outcomes of [177Lu]Lu-PSMA-617 (177Lu-PSMA-617) after sipuleucel-T in patients with metastatic castration-resistant prostate cancer (mCRPC): a real-world prostate cancer disease observation (PRECISION) data platform analysis
Neal D. Shore et al.
Poster presented at ASCO GU 2026
Prognostic Significance of Baseline and Longitudinal Depressive Symptoms in Men with Advanced Prostate Cancer (PC): Results from the IRONMAN Registry
Rana McKay
Poster presented at ASCO GU 2026
Real-World Cost Effectiveness of Androgen Receptor Pathway Inhibitors for Metastatic Hormone Sensitive Prostate Cancer: An Economic Evaluation Utilizing Data from the International Registry for Men with Advanced Prostate Cancer (IRONMAN)
Rebecca Green et al.
Poster presented at ASCO 2026
Real-world effectiveness of systemic therapies after [177Lu]Lu-PSMA-617 (177-Lu-PSMA-617) treatment in patients with metastatic castration-resistant prostate cancer (mCRPC): a prostate cancer disease observation (PRECISION) data platform analysis.
Xiao Wei
Poster presented at GU 2026
Real-world outcomes of [177Lu]Lu-PSMA-617 (177Lu-PSMA-617) in taxane-naive patients with metastatic castration resistant prostate cancer (mCPRC): a prostate cancer disease observation (PRECISION) data platform analysis
Daniel George
Poster presented at ASCO GU 2026
Real-world use of novel hormonal therapies in European and North American patients with metastatic hormone-sensitive prostate cancer
Zdravko Vassilev
Poster presented at ASCO GU 2026
Sequencing of therapeutic agents before and after metastatic castration-resistant prostate cancer (mCRPC) diagnosis in an international real-world setting
Manami Bhattacharya
Poster presented at ASCO GU 2026
Treatment utilization among patients with metastatic hormone-sensitive prostate cancer in real-world US cancer disease observation (PRECISION) data platform analysis
Daniel George
Poster presented at ASCO GU 2026
Disparities in prostate-specific membrane antigen (PSMA)-targeted imaging utilization among patients with advanced prostate cancer
Wei, Xiao
Poster Presented at PCF 2025
Prostate-specific membrane antigen targeted imaging utilization and its association with disease progression and treatment changes in patients with metastatic hormone sensitive prostate cancer and metastatic castration-resistant prostate cancer
Julian Chavarriaga et al.
Poster presented at ASTRO 2025
Relationship between undetectable PSA nadir and outcomes for patients with metastatic hormone sensitive prostate cancer in IRONMAN, the International Registry for Men with Advanced Prostate Cancer
Hannah McManus et al.
Poster presented at ASCO GU 2025
Impact of first-line hormone therapies at enrollment and subjective cognitive function over time among metastatic prostate cancer survivors: an international study
Michelle Sodipo
AACR 2025
The International Registry for Men with Advanced Prostate Cancer
Mucci, L. et al
Poster presented at: ASCO Genitourinary Cancers Symposium; 2023 Jan 19-21; San Francisco, CA
Marital status, living arrangement, and overall survival among individuals with advanced prostate cancer in the IRONMAN cohort
Chen, N. et al
Poster presented at: AACR Annual Meeting; 2023 Apr 14-19; Orlando, FL
Click here to view the abstract
The International Registry for Men with Advanced Prostate Cancer
George, D.J. et al
Poster presented at: ASCO Genitourinary Cancers Symposium; 2022 Feb 17-19; San Fransisco, CA.
Click here to view the abstract
First Look at Patient Reported Outcomes from IRONMAN, the International Registry of Men with Advanced Prostate Cancer
Rencsok, E., et al
Poster presented at: ASCO Genitourinary Cancers Symposium; 2022 Feb 17-19; San Fransisco, CA.
Click here to view the conference
First 500 Patients of IRONMAN: International Registry for Men with Advanced Prostate Cancer
George, D.J. et al
Poster presented at: PCF Annual Scientific Retreat; 2019 Oct 24-26; Carlsbad, CA
Click here to view the abstract
Patient Reported Outcomes Ameng Men with Advanced Prostate Cancer: Results from the IRONMAN Registry
Mucci, L. et al
Poster presented at: PCF Annual Scientific Retreat; 2019 Oct 24-26; Carlsbad, CA
Click here to view the abstract